JP2005503339A5 - - Google Patents

Download PDF

Info

Publication number
JP2005503339A5
JP2005503339A5 JP2002582924A JP2002582924A JP2005503339A5 JP 2005503339 A5 JP2005503339 A5 JP 2005503339A5 JP 2002582924 A JP2002582924 A JP 2002582924A JP 2002582924 A JP2002582924 A JP 2002582924A JP 2005503339 A5 JP2005503339 A5 JP 2005503339A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002582924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503339A (ja
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed filed Critical
Priority claimed from PCT/US2002/011397 external-priority patent/WO2002085351A1/en
Publication of JP2005503339A publication Critical patent/JP2005503339A/ja
Publication of JP2005503339A5 publication Critical patent/JP2005503339A5/ja
Pending legal-status Critical Current

Links

JP2002582924A 2001-04-11 2002-04-11 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整 Pending JP2005503339A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08
PCT/US2002/011397 WO2002085351A1 (en) 2001-04-11 2002-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer

Publications (2)

Publication Number Publication Date
JP2005503339A JP2005503339A (ja) 2005-02-03
JP2005503339A5 true JP2005503339A5 (xx) 2008-11-20

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002582924A Pending JP2005503339A (ja) 2001-04-11 2002-04-11 前立腺患者における健康関連クオリティオブライフ及び病気進行までの健康関連クオリティ適応時間の有利な調整

Country Status (10)

Country Link
EP (1) EP1379238A1 (xx)
JP (1) JP2005503339A (xx)
CN (1) CN1514727A (xx)
AR (1) AR033465A1 (xx)
BR (1) BR0205970A (xx)
CA (1) CA2442591A1 (xx)
IL (1) IL158071A0 (xx)
MX (1) MXPA03009277A (xx)
PE (1) PE20021032A1 (xx)
WO (1) WO2002085351A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
EP2037912A2 (en) * 2006-05-15 2009-03-25 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EP2190433A2 (en) 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
CN117751099A (zh) * 2021-08-05 2024-03-22 中国药科大学 酰胺类化合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1003740A2 (en) * 1997-08-04 2000-05-31 Abbott Laboratories Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagoists

Similar Documents

Publication Publication Date Title
JP2004532269A5 (xx)
JP2004537984A5 (xx)
JP2006503960A5 (xx)
JP2006502250A5 (xx)
JP2003305787A5 (xx)
JP2004537871A5 (xx)
JP2003193065A5 (xx)
JP2003321523A5 (xx)
JP2004155888A5 (xx)
JP2004188303A5 (xx)
JP2005232258A5 (xx)
JP2004530731A5 (xx)
JP2005532980A5 (xx)
JP2004522835A5 (xx)
JP2004537572A5 (xx)
JP2004518010A5 (xx)
JP2005503339A5 (xx)
JP2000503729A5 (xx)
JP2005506321A5 (xx)
JP2003268293A5 (xx)
JP2004294750A5 (xx)
JP2004143162A5 (xx)
JP2004091766A5 (xx)
JP2005537788A5 (xx)
JP2003081764A5 (xx)